A 58-year-old man with a 10-year history of type 2 diabetes and hypertension presents with stable angina. His LDL cholesterol is 145 mg/dL despite lifestyle modifications. Coronary angiography reveals 60% stenosis in the left anterior descending artery. Which drug is the first-line agent to reduce his cardiovascular risk and slow atherosclerotic progression?

Question

Accepted Answer

C. Atorvastatin. ## Rationale for Statin as First-Line Therapy

**Key Point:** Statins are the gold-standard first-line agents for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). They reduce LDL cholesterol by 30–55% and lower cardiovascular events by ~30% independent of baseline LDL.

### Mechanism of Action
Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. This leads to:
1. Decreased hepatic cholesterol production
2. Upregulation of LDL receptors
3. Enhanced clearance of LDL from circulation
4. Pleiotropic anti-inflammatory and plaque-stabilizing effects

### Evidence Base
**High-Yield:** Major trials (4S, WOSCOPS, CARE, LIPID, HPS, ASCOT-LLA) demonstrate that statins reduce:
- Myocardial infarction incidence
- Stroke risk
- Cardiovascular mortality
- All-cause mortality (in secondary prevention)

### Comparison with Other Lipid-Lowering Agents

| Agent | Role | When Used |
|-------|------|----------|
| **Statin** | First-line; reduces LDL 30–55% | All patients with ASCVD or high risk |
| **Ezetimibe** | Adjunctive; reduces LDL 15–20% | Added if statin monotherapy insufficient |
| **Bempedoic acid** | Uricosuric; reduces LDL 15–20% | Statin-intolerant patients (newer agent) |
| **PCSK9 inhibitor** | Potent; reduces LDL 50–70% | Statin-intolerant or very high-risk patients |

**Clinical Pearl:** In this patient with diabetes, hypertension, and angiographic CAD (secondary prevention), high-intensity statin therapy (e.g., atorvastatin 40–80 mg daily) is guideline-mandated. The LDL goal is typically <70 mg/dL or even <55 mg/dL in very high-risk patients.

**Mnemonic:** **STATIN** = **S**tatin **T**herapy **A**ddresses **T**hree **I**ssues **N**ow (LDL reduction, plaque stabilization, inflammation suppression).

## Why This Patient Needs a Statin
- Established CAD (60% LAD stenosis) = secondary prevention
- Diabetes + hypertension = high-risk phenotype
- LDL 145 mg/dL = above goal
- No contraindication mentioned (normal liver/muscle function assumed)

Answer

A. Ezetimibe

Answer

B. Bempedoic acid

Answer

D. PCSK9 inhibitor

Explanation

Rationale for Statin as First-Line Therapy

Mechanism of Action

Evidence Base

Comparison with Other Lipid-Lowering Agents

Why This Patient Needs a Statin

Practice similar questions

Join our NEET PG community

Agent	Role	When Used
Statin	First-line; reduces LDL 30–55%	All patients with ASCVD or high risk
Ezetimibe	Adjunctive; reduces LDL 15–20%	Added if statin monotherapy insufficient
Bempedoic acid	Uricosuric; reduces LDL 15–20%	Statin-intolerant patients (newer agent)
PCSK9 inhibitor	Potent; reduces LDL 50–70%	Statin-intolerant or very high-risk patients